JP2022507741A5 - - Google Patents
Info
- Publication number
- JP2022507741A5 JP2022507741A5 JP2021527208A JP2021527208A JP2022507741A5 JP 2022507741 A5 JP2022507741 A5 JP 2022507741A5 JP 2021527208 A JP2021527208 A JP 2021527208A JP 2021527208 A JP2021527208 A JP 2021527208A JP 2022507741 A5 JP2022507741 A5 JP 2022507741A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- seq
- binding site
- antibody
- isolated antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023072027A JP7587629B2 (ja) | 2018-11-19 | 2023-04-26 | アンタゴニストcd40モノクローナル抗体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769514P | 2018-11-19 | 2018-11-19 | |
| US62/769,514 | 2018-11-19 | ||
| PCT/US2019/062011 WO2020106620A1 (en) | 2018-11-19 | 2019-11-18 | Antagonistic cd40 monoclonal antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023072027A Division JP7587629B2 (ja) | 2018-11-19 | 2023-04-26 | アンタゴニストcd40モノクローナル抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022507741A JP2022507741A (ja) | 2022-01-18 |
| JP2022507741A5 true JP2022507741A5 (cg-RX-API-DMAC7.html) | 2022-11-01 |
| JP7271666B2 JP7271666B2 (ja) | 2023-05-11 |
Family
ID=68848451
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021527208A Active JP7271666B2 (ja) | 2018-11-19 | 2019-11-18 | アンタゴニストcd40モノクローナル抗体およびその使用 |
| JP2023072027A Active JP7587629B2 (ja) | 2018-11-19 | 2023-04-26 | アンタゴニストcd40モノクローナル抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023072027A Active JP7587629B2 (ja) | 2018-11-19 | 2023-04-26 | アンタゴニストcd40モノクローナル抗体およびその使用 |
Country Status (20)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11220550B2 (en) | 2017-05-25 | 2022-01-11 | Bristol-Myers Squibb Company | Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity |
| AR117091A1 (es) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| JP2023539736A (ja) * | 2020-08-25 | 2023-09-19 | ブリストル-マイヤーズ スクイブ カンパニー | 拮抗性cd40モノクローナル抗体で自己免疫性疾患を処置する方法 |
| CA3202891A1 (en) | 2021-01-28 | 2022-08-04 | Kara Olson | Compositions and methods for treating cytokine release syndrome |
| WO2023274007A1 (zh) * | 2021-06-29 | 2023-01-05 | 舒泰神(北京)生物制药股份有限公司 | 特异性识别cd40的抗体及其应用 |
| JP7833531B2 (ja) * | 2021-07-14 | 2026-03-19 | 舒泰神(北京)生物製薬股フン有限公司 | Cd40を特異的に認識する抗体およびその使用 |
| WO2023186111A1 (zh) * | 2022-04-02 | 2023-10-05 | 和铂医药(上海)有限责任公司 | 一种靶向cd40的抗原结合蛋白及其制备和应用 |
| CN117264063B (zh) * | 2023-03-22 | 2024-04-23 | 赛业(苏州)生物科技有限公司 | 一种抗gpc3抗体及其应用 |
| CN119490596B (zh) * | 2023-08-21 | 2026-01-23 | 菲鹏生物股份有限公司 | 一种抗人IgM抗体及其应用 |
| KR20250116195A (ko) | 2024-01-24 | 2025-08-01 | 서울대학교산학협력단 | Cd40에 특이적으로 결합하는 항체 및 이의 용도 |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| US20250277048A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025235670A1 (en) | 2024-05-07 | 2025-11-13 | Eledon Pharmaceuticals, Inc. | Use of anti-cd40 ligand antibodies for immunosuppression in islet cell transplantation |
| WO2025235683A1 (en) | 2024-05-07 | 2025-11-13 | Eledon Pharmaceuticals, Inc. | Methods and compositions for prevention of transplant rejection |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| GB2353887B (en) | 1999-09-04 | 2003-09-24 | Ibm | Speech recognition system |
| WO2003028809A1 (en) * | 2001-10-02 | 2003-04-10 | Chiron Corporation | Methods of therapy for b-cell malignancies |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20080199471A1 (en) | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
| PL1682177T3 (pl) * | 2003-11-04 | 2011-03-31 | Novartis Vaccines & Diagnostics Inc | Zastosowanie antagonistycznych przeciwciał anty-CD40 do leczenia przewlekłej białaczki limfocytowej |
| PT1684805E (pt) * | 2003-11-04 | 2010-10-26 | Novartis Vaccines & Diagnostic | Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento do mieloma múltiplo |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| AU2004287879C1 (en) * | 2003-11-04 | 2011-05-26 | Novartis Vaccines And Diagnostics, Inc. | Antagonist anti-CD40 monoclonal antibodies and methods for their use |
| RU2006141632A (ru) * | 2004-04-27 | 2008-06-10 | Новартис Вэксинес Энд Дайэгностикс, Инк. (Us) | Антагонистические моноклональные анти-cd40-антитела и способы их применения |
| EP3342782B1 (en) | 2004-07-15 | 2022-08-17 | Xencor, Inc. | Optimized fc variants |
| US20080057070A1 (en) * | 2004-11-04 | 2008-03-06 | Chiron Corporation | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
| US20150315284A1 (en) | 2004-11-09 | 2015-11-05 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
| WO2006127910A2 (en) | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated erythropoietin formulations |
| AU2006304387A1 (en) | 2005-10-14 | 2007-04-26 | Medimmune, Llc | Cell display of antibody libraries |
| CA2669412A1 (en) | 2007-01-23 | 2008-07-31 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| US8629245B2 (en) | 2007-05-01 | 2014-01-14 | Research Development Foundation | Immunoglobulin Fc libraries |
| WO2009060198A1 (en) | 2007-11-09 | 2009-05-14 | Peregrine Pharmaceuticals, Inc. | Anti-vegf antibody compositions and methods |
| US10053513B2 (en) | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| EP2796467B1 (en) | 2010-03-31 | 2018-03-28 | Boehringer Ingelheim International GmbH | Anti-CD40 antibodies |
| US9303083B2 (en) | 2010-10-04 | 2016-04-05 | Riken | Therapeutic agent for malignant tumors expressing MHC class II |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| US9409950B2 (en) | 2010-12-23 | 2016-08-09 | Biogen Ma Inc. | Linker peptides and polypeptides comprising same |
| NO2699601T3 (cg-RX-API-DMAC7.html) * | 2011-04-21 | 2018-06-16 | ||
| KR102037432B1 (ko) * | 2011-04-29 | 2019-11-27 | 아펙시젠, 인코포레이티드 | 항-cd40 항체 및 사용 방법 |
| KR20250078601A (ko) | 2011-09-30 | 2025-06-02 | 추가이 세이야쿠 가부시키가이샤 | 항원의 소실을 촉진시키는 항원 결합 분자 |
| TW201817745A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
| EP4624490A3 (en) | 2012-02-09 | 2025-11-05 | Chugai Seiyaku Kabushiki Kaisha | Modified fc region of antibody |
| GB201203051D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| WO2014006217A1 (en) | 2012-07-06 | 2014-01-09 | Genmab B.V. | Dimeric protein with triple mutations |
| TWI855488B (zh) | 2012-08-24 | 2024-09-11 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
| CA2888763A1 (en) | 2012-10-30 | 2014-05-08 | Apexigen, Inc. | Anti-cd40 antibodies and methods of use |
| US20140294812A1 (en) | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
| GB201308658D0 (en) | 2013-05-14 | 2013-06-26 | Isis Innovation | Antibodies |
| WO2015134988A1 (en) | 2014-03-07 | 2015-09-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
| PL3177643T3 (pl) | 2014-08-04 | 2019-09-30 | F.Hoffmann-La Roche Ag | Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T |
| EP3626740A1 (en) * | 2014-08-14 | 2020-03-25 | F. Hoffmann-La Roche AG | Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1 |
| US20170233485A1 (en) | 2014-08-18 | 2017-08-17 | Biogen Ma Inc. | Anti-cd40 antibodies and uses thereof |
| JP6805142B2 (ja) | 2014-11-21 | 2020-12-23 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Cd73に対する抗体およびその使用 |
| HRP20201334T1 (hr) | 2015-04-17 | 2020-11-27 | Bristol-Myers Squibb Company | Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba |
| JP6518917B2 (ja) * | 2015-05-29 | 2019-05-29 | アッヴィ・インコーポレイテッド | 抗cd40抗体およびその使用 |
| PE20180315A1 (es) * | 2015-06-29 | 2018-02-09 | Bristol Myers Squibb Co | Anticuerpos para cd40 |
| MX2017016502A (es) | 2015-06-29 | 2018-03-12 | Univ Rockefeller | Anticuerpos contra cd40 con actividad agonista mejorada. |
| PE20181367A1 (es) | 2015-09-30 | 2018-08-27 | Janssen Biotech Inc | Anticuerpos agonistas que se unen especificamente a cd40 humana y metodos de uso |
| EP3523329A1 (en) | 2016-10-06 | 2019-08-14 | GlaxoSmithKline Intellectual Property Development Limited | Antibodies with reduced binding to process impurities |
| PE20250933A1 (es) | 2017-03-14 | 2025-04-02 | Five Prime Therapeutics Inc | Anticuerpos de union a vista a ph acido |
| US20200095323A1 (en) | 2017-03-20 | 2020-03-26 | The General Hospital Corporation | MITIGATING Fc-Fc RECEPTOR INTERACTIONS IN CANCER IMMUNOTHERAPY |
| US20200148779A1 (en) | 2017-05-25 | 2020-05-14 | Bristol-Myers Squibb Company | MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH |
| US11220550B2 (en) | 2017-05-25 | 2022-01-11 | Bristol-Myers Squibb Company | Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity |
| MX2019013132A (es) | 2017-05-25 | 2020-01-27 | Bristol Myers Squibb Co | Anticuerpos que comprenden regiones constantes pesadas modificadas. |
| EP3704158A1 (en) | 2017-11-03 | 2020-09-09 | Novartis AG | Anti-cd40 antibodies for use in treatment of sjögren's syndrome |
| CA3119341A1 (en) | 2018-11-16 | 2020-05-22 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor |
| AR117091A1 (es) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| JP2022513653A (ja) | 2018-11-28 | 2022-02-09 | ブリストル-マイヤーズ スクイブ カンパニー | 修飾された重鎖定常領域を含む抗体 |
-
2019
- 2019-11-15 AR ARP190103362A patent/AR117091A1/es unknown
- 2019-11-18 BR BR112021009140-8A patent/BR112021009140A2/pt not_active Application Discontinuation
- 2019-11-18 WO PCT/US2019/062011 patent/WO2020106620A1/en not_active Ceased
- 2019-11-18 IL IL283104A patent/IL283104B2/en unknown
- 2019-11-18 AU AU2019385331A patent/AU2019385331B2/en active Active
- 2019-11-18 EP EP19818398.0A patent/EP3883652A1/en active Pending
- 2019-11-18 EA EA202191359A patent/EA202191359A1/ru unknown
- 2019-11-18 PE PE2021000727A patent/PE20211293A1/es unknown
- 2019-11-18 CN CN201980076479.8A patent/CN113164781B/zh active Active
- 2019-11-18 US US16/686,596 patent/US11261258B2/en active Active
- 2019-11-18 KR KR1020217018573A patent/KR102627246B1/ko active Active
- 2019-11-18 MX MX2021005565A patent/MX2021005565A/es unknown
- 2019-11-18 CA CA3120358A patent/CA3120358C/en active Active
- 2019-11-18 CN CN202310098945.0A patent/CN116003608B/zh active Active
- 2019-11-18 SG SG11202104776VA patent/SG11202104776VA/en unknown
- 2019-11-18 MY MYPI2021002555A patent/MY204740A/en unknown
- 2019-11-18 JP JP2021527208A patent/JP7271666B2/ja active Active
- 2019-11-19 TW TW108142021A patent/TWI800694B/zh active
-
2020
- 2020-10-26 US US17/080,626 patent/US11254750B2/en active Active
-
2021
- 2021-05-11 CL CL2021001230A patent/CL2021001230A1/es unknown
- 2021-05-18 ZA ZA2021/03353A patent/ZA202103353B/en unknown
- 2021-06-11 CO CONC2021/0007691A patent/CO2021007691A2/es unknown
-
2022
- 2022-01-19 US US17/579,468 patent/US11926673B2/en active Active
- 2022-01-31 US US17/588,518 patent/US11773178B2/en active Active
- 2022-02-11 US US17/670,223 patent/US11795231B2/en active Active
-
2023
- 2023-04-26 JP JP2023072027A patent/JP7587629B2/ja active Active
- 2023-08-22 US US18/453,691 patent/US12409223B2/en active Active
-
2024
- 2024-02-14 US US18/441,998 patent/US12419953B2/en active Active
-
2025
- 2025-01-17 AU AU2025200355A patent/AU2025200355A1/en active Pending
- 2025-08-28 US US19/313,526 patent/US20260151479A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11667722B2 (en) | Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases | |
| US20220267476A1 (en) | Multispecific antibody constructs | |
| US10851172B2 (en) | Humanized antibodies against CD269 (BCMA) | |
| KR102143506B1 (ko) | 변형된 단백질 및 펩티드 | |
| JP6746564B2 (ja) | Il−23a及びtnf−アルファを標的とする化合物ならびにその使用 | |
| RU2604196C2 (ru) | Антитела против cd70 | |
| CN103946240B (zh) | 对人ox40具有特异性的抗体分子 | |
| TWI280980B (en) | Human antibodies that bind human IL-12 and methods for producing | |
| ES2923143T3 (es) | Anticuerpos monoclonales antagonistas contra CD40 y sus usos | |
| CN103154029B (zh) | 抗人tweak的抗体及其用途 | |
| JP2014513953A5 (cg-RX-API-DMAC7.html) | ||
| WO2015137843A1 (ru) | Анти-il-17-антитела, способ их получения и способ применения | |
| JP2022093640A (ja) | 抗il-1治療に関する新しい適応症 | |
| JP2020509756A5 (cg-RX-API-DMAC7.html) | ||
| KR20170023212A (ko) | 보체-관련 장애의 예방 및 치료를 위한 C3b 항체 및 방법 | |
| TW200831533A (en) | Interleukin-13 binding proteins | |
| JP2020521458A5 (cg-RX-API-DMAC7.html) | ||
| JP2014530611A5 (cg-RX-API-DMAC7.html) | ||
| JP2014511844A5 (cg-RX-API-DMAC7.html) | ||
| AU2023282504A1 (en) | Igf1r antibodies | |
| TW202540170A (zh) | 抗原結合蛋白 | |
| TH2101002815A (th) | โมโนโคลนอลแอนติบอดีที่เป็นแอนทาโกนิสท์ต่อ cd40 และการใช้แอนติบอดีดังกล่าว | |
| NZ777121B2 (en) | Antagonistic cd40 monoclonal antibodies and uses thereof | |
| NZ777121A (en) | Antagonistic cd40 monoclonal antibodies and uses thereof | |
| WO2023025309A1 (zh) | 一种cdc平台抗体 |